ALDH5A1 and breast ductal adenocarcinoma: For example, the gene TNFRSF17 had been used as a drug target for multiple myeloma, the drug Belantamab Mafodotin targeted was approved by the FDA in 2020.[86] Gene ALDH5A1 has been suggested as a poor prognostic marker for papillary thyroid carcinoma and a new potential target for human breast ductal carcinoma by gene knock-out, cell proliferation, Transwell migration/invasion assay, wound healing, and qRT-PCR methods.